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 Introduction 
 Sixty years of lithium treatment in psychiatry yielded 
a still continuing stream of knowledge on the pharmaco-
logical and therapeutic effects as well as the effectiveness 
of this fascinating alkali ion. One of the lightest metallic 
elements had a heavy impact on the concepts and practice 
of modern psychiatry. Some scientific studies on lithium 
and clinical experience collected during recent decades 
partly confirmed early anecdotal findings, and partly re-
modeled and integrated them into updated, more precise 
and comprehensive concepts, thus making previous ob-
servations better understood  [1, 2] . Other studies detect-
ed or redetected important aspects of lithium which ei-
ther are still to be discussed on a hypothetical level such 
as its ‘neuroprotective’ effects, or which are supported by 
very good scientific evidence but still did not find their 
way into everyday clinical practice and existing guide-
lines. The antisuicidal and anti-aggressive properties of 
lithium reflect this latter situation. Although antidepres-
sants have been in use for more than 50 years, it is disap-
pointing that no valid data exist to prove a suicide- or 
mortality-reducing effect, with the consequence that 
usually drug regulatory agencies do not consider reduc-
ing the death rate as an essential criterion for approval of 
a new antidepressant or mood stabilizer. This is rather 
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 Abstract 
 From a practical point of view, the well-proven antisuicidal 
and anti-aggressive effects of lithium are of utmost impor-
tance for a rational, safe and economical treatment of pa-
tients with affective disorders. Regular lithium long-term 
treatment reduces the otherwise 2- to 3-fold increased mor-
tality of untreated patients with severe affective disorders 
down to the level of the general population. This is mainly 
due to the reduced suicide risk. Many international studies 
have confirmed this fascinating property of lithium which so 
far has not been demonstrated with comparable evidence 
for any other psychotropic compound. The antisuicidal ef-
fects of lithium might possibly be related to its anti-aggres-
sive effects which have been shown in various species, pop-
ulations and settings, such as animals, inhabitants of nursing 
homes for the elderly, mentally handicapped subjects, chil-
dren and adolescents with hyperactive, hostile and aggres-
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correction units and prisons.  Copyright © 2010 S. Karger AG, Basel 
 Published online: May 7, 2010 
 Prof. Dr. med. Bruno Müller-Oerlinghausen 
 Bartningallee 11–13 
 DE–10557 Berlin (Germany) 
 Tel. +49 30 2336 2940, Fax +49 30 2336 2935
E-Mail bmoe  @  zedat.fu-berlin.de 
 © 2010 S. Karger AG, Basel
0302–282X/10/0621–0043$26.00/0 
 Accessible online at:
www.karger.com/nps 
 Müller-Oerlinghausen /Lewitzka Neuropsychobiology 2010;62:43–4944
astonishing since for lithium salts such data do exist. In 
what follows, we will sketch the key studies and the his-
tory of this important research area. More comprehen-
sive reviews of the existing literature can be found else-
where  [3] .
 Does Regular Lithium Long-Term Treatment 
Diminish the Risk of Suicide in Patients with 
Affective Disorders? 
 Suicide Risk and Mortality of Patients with Affective 
Disorders 
 Patients with affective disorders exhibit a 2–3 times 
increased mortality when compared to the general popu-
lation  [4–7] . This excess mortality is caused primarily by 
the possibly 30- to 70-fold higher suicide-related mortal-
ity  [8] – which is particularly high in patients with a his-
tory of suicide attempts  [9, 10] . The meta-analysis by 
Guze and Robins  [11] calculated the lifetime suicide risk 
as 15% for affective disorders, whereas 20 years later 
Goodwin and Jamison  [12] , based on more recent litera-
ture, reported an overall risk of 19%.
 According to Harris and Barraclough  [13] , the suicide-
related standardized mortality rate (SMR)  [14] is 21.24 in 
major depression and 11.73 in bipolar disorder, with, 
however, large confidence intervals. Although some stud-
ies found a somewhat lower suicide rate in bipolar as 
compared to unipolar patients  [15, 16] , others found high-
er rates in bipolar patients  [17–19] , particularly in bipolar 
II patients.
 The intriguing question whether long-term medica-
tion with lithium salts can improve the course of the 
manic-depressive disease or of affective disorders in 
terms of suicide prevention has been given little attention 
until the 80s.
 Early Studies 
 Barraclough  [20] was one of the first investigators pos-
tulating a potential association between lithium long-
term medication and suicide prevention. Based on a de-
tailed analysis of the charts of 100 suicide victims he con-
cluded that about 20% of the suicides could have been 
prevented by adequate lithium medication. The first sys-
tematic retrospective study demonstrating a highly sig-
nificant reduction of suicide attempts in a sample of 64 
high-risk patients, 46 bipolar and 11 schizoaffective, dur-
ing long-term lithium treatment was published in 1992 
by the Berlin research group  [21] . The authors empha-
sized that suicides and suicide attempts occurred nearly 
exclusively in a group of 13 patients who had taken lithi-
um irregularly or had stopped the medication.
 Felber’s group in Dresden analyzing suicide attempts 
during accumulated periods on and off lithium had very 
similar findings: 90% of the suicide attempts occurred in 
the lithium-free period  [22] .
 Several studies on the mortality of affective disorders 
during lithium long-term treatment by Coppen et al.  [23] 
and by the International Group for the Study of Lithium-
Treated Patients (IGSLI)  [14, 24] demonstrated that the 
SMR of patients with affective disorders during adequate 
lithium medication is normalized down to the level of the 
general population 1 . Coppen  [25] reviewed the studies 
existing in the mid-nineties on the suicide rates in pa-
tients on versus off lithium and concluded that adequate 
lithium medication reduces the suicide-related mortality 
by 82%.
 The IGSLI Studies 
 In the IGSLI main study, well-documented data on the 
course of illness of 827 patients with affective disorders 
from lithium clinics in Austria, Canada, Denmark, and 
Germany, who had been treated with lithium for at least 
6 months, were evaluated  [14, 24] . Fifty-five percent of the 
patients were bipolar, 25% unipolar, 2% unipolar-manic, 
16% schizoaffective, and 2% had other diagnoses. At on-
set of the lithium prophylaxis, patients were 41 years old 
on average. The mean duration of lithium treatment was 
81 months (6–21 years), equaling 5,600 patient-years  [14, 
24] .
 The ratio of 44 observed and 38 expected cases of 
deaths is not statistically different from 1.0, which is the 
mortality of the general population. Thus, the expected 
2- to 3-fold excess mortality in patients with affective dis-
orders (see above) does no more exist in this lithium-
treated patient sample.
 Bipolar patients do not differ essentially from other 
diagnostic groups in this respect.
 Although the specific suicide-related SMR is still high-
er than in the general population, it can be clearly shown 
that it is definitely lower in all diagnostic groups com-
pared to what could be expected in untreated patient 
samples.
 To weaken this finding, it might be speculated that 
patients willing to accept long-term treatment may ex-
hibit a lower suicide risk, although this does not appear 
very likely when accounting for the fact that those pa-
tients would suffer from particularly severe courses of 
their disease. A further analysis of the IGSLI material 
could refute this argument: during the first year of lithi-
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um treatment, patients showed a 2-fold increased overall 
mortality and a 17-fold increased suicide-related mortal-
ity compared with the general population. During later 
lithium treatment, the SMR normalized thus indicating 
that patients who accept lithium prophylaxis actually ex-
hibit a high suicide risk  [26] . The Boston group also re-
ported that after abrupt discontinuation of lithium med-
ication the suicide risk rises particularly high  [27] .
 Further Studies and Meta-Analyses 
 A meta-analysis of the data collected by the late nine-
ties revealed that the risk of suicidal acts in bipolar pa-
tients off lithium was 7–8 times higher than in those on 
lithium  [28] . Furthermore, the findings by Guzzetta et al. 
 [29] support the reports by Coppen and the IGSLI that
the antisuicidal effect also holds true for patients with 
recurrent depressions.
 Linking regional lithium prescription rates with the 
Danish suicide register, Kessing et al.  [30] added another 
impressive piece of evidence to the existing data on lith-
ium’s antisuicidal effect. There also exist convincing 
findings from controlled prospective studies. Cipriani et 
al.  [31] reviewed 22 randomized controlled trials and 
found that patients on lithium were less likely to die from 
suicide, as compared to other compounds or placebo. Ad-
ditional proof comes from the first controlled trial with 
lithium versus placebo as an adjunctive treatment in a 
large sample of high-risk patients. Suicidal events were 
defined as the endpoint  [32] . Whereas the number of sui-
cide attempts did not differ between treatment groups, a 
statistically significant superiority of lithium in terms of 
completed suicides was observed, whereas in a retrospec-
tive chart review of long-term treated bipolar patients 
from a single private practice nonfatal suicidal behavior 
was not different in patients on lithium and those on an-
ticonvulsants  [33] .
 Questions 
 There are several intriguing questions related to the 
mechanism of the antisuicidal effect of lithium and its 
potential specificity. First of all, is the antisuicidal effect 
coupled directly to the antidepressant effect of lithium? 
Several reports point to a mechanism separate from lith-
ium’s antidepressant action  [34] . It has been speculated 
that the antisuicidal effect is associated with the well-
proven serotonin-agonistic effect in biochemical terms, 
and with the well-established anti-aggressive effect of 
lithium in clinical terms  [35] . Secondly, is the antisuicid-
al effect of lithium shared by other compounds such as 
antidepressants, neuroleptics or mood stabilizers? So far, 
in various trials using different methodologies, lithium 
has been shown clearly superior to other mood stabilizers 
in terms of suicide prevention  [36–40] .
 Conclusion 
 ‘Does lithium save lives?’ – the question raised in an 
editorial  [41] , can now be answered conclusively: yes, it 
does, if the treatment is applied and monitored in a ratio-
nal, careful and individualized way. While there are rare 
negative findings in this respect  [42] , they can most like-
ly be explained by incomplete patient follow-up and in-
sufficient information on patients’ compliance with lith-
ium. This saving of lives considerably adds to the prefer-
ence of lithium when the cost-effectiveness of treatment 
with various mood stabilizers is assessed  [43] .
 Does Lithium Reduce Pathological Aggression? 
 The first report on the anti-aggressive effect of lithium 
was described by John F. Cade  [44] who documented that 
lithium would be effective in cases of restless psycho-
pathic mental defectives in a similar way as a prefrontal 
leukotomy.
 Twenty years later, a number of Scandinavian case re-
ports were published. Forssmann and Walinder  [45] tried 
lithium for various indications. They reported 18 cases 
with aggression as the predominant clinical feature and 
pointed to amazingly good results with lithium.
 Baastrup  [46] characterized a female aggressive pa-
tient endangering herself and others. Lithium was the 
only drug to control this behavior although the patient 
was not manic-depressive.
 Clinical trials on the effect of lithium on aggression 
included mainly four different groups of patients: (a) chil-
dren with behavioral disturbances, (b) patients with 
mental handicaps, (c) adult psychiatric populations,
and (d) persons with uncontrolled fit of rage. There is, 
however, some overlapping between these diagnostic 
groups.
 Children with Behavioral Disturbances 
 The validity of studies conducted in children with ag-
gressive behavior suffers from methodological problems. 
Most studies involved extremely heterogeneous patients. 
At least 4 double-blind, placebo-controlled studies were 
performed since 1995  [47–50] .
 Campell et al.  [47] examined 61 children aged 5.2–12.9 
years with severe aggressiveness, explosiveness and dis-
ruptiveness. The children had not responded to previous 
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treatment. They were treated with lithium or haloperidol 
or placebo for 4 weeks. Both substances, lithium and hal-
operidol, reduced target symptoms such as hyperactivity, 
aggression and hostility, but side effects occurred signif-
icantly more often on haloperidol.
 In the early 1990s, studies were often published which 
failed to replicate these results. The study of Carlson et al. 
 [51] only showed 3 of 11 children with significant im-
provement as to self-control, aggression and irritability.
 A second placebo-controlled double-blind trial was 
performed also by Campbell et al.  [48] . Fifty children 
with severe aggressive and impulsive symptoms as part 
of a conduct disorder were treated with lithium or pla-
cebo for 6 weeks followed by 2 weeks on placebo. The 
findings were not as much in favor of lithium as those of 
the former study by Campell et al.  [47] .
 Rifkin et al.  [49] included 33 adolescent inpatients and 
administered lithium or placebo for 2 weeks. 8.3% of 
those who completed the study receiving placebo versus 
21.4% of those receiving lithium were considered re-
sponders. The authors assumed the major limitation of 
this study and the possible reason for the nonsignificant 
results was the short period of treatment.
 Another study conducted by Malone et al.  [50] investi-
gated different aggression subtypes related to treatment 
response. They included 28 aggressive conduct-disor-
dered children (mean age 12.69 years) and treated them 
in a double-blind manner either with lithium or placebo. 
They found that treatment response with lithium corre-
lated rather with the affective subtype than with the pred-
atory subtype of aggression. A further study of the same 
authors  [52] on the efficacy of lithium in the treatment of 
aggression achieved more favorable results for lithium. 
Lithium turned out to be statistically and clinically supe-
rior to placebo. They included 86 inpatients with conduct 
disorder and treated them in a double-blind manner with 
lithium or placebo for 4 weeks. Sixteen of 20 subjects in 
the lithium group were responders versus 6 of 20 in the 
placebo group. In more than 50% of the subjects in the 
lithium group adverse side effects like vomiting, nausea 
and increased urinary frequency were observed.
 Patients with Mental Handicaps 
 Ten to thirty-five percent of patients with mental 
handicaps show self-injurious behavior like head-bang-
ing, biting, and scratching oneself. Explosive behavior 
complicates the daily life of these patients and their fam-
ilies and hospitalization, therefore, is often unavoidable. 
The treatment of aggressive behavior presents a challenge 
to every clinician.
 Since the 1970s, lithium therapy was included in phar-
macological attempts to reduce the most severe aggres-
sive symptoms. Only studies in which the authors had 
clearly diagnosed the patients as mentally handicapped 
are listed in the following paragraph.
 The first open trial on aggression was conducted by 
Dostal and Zvolsky  [53] . They investigated 14 adolescent, 
mentally handicapped patients and showed a beneficial 
effect under lithium therapy. Most of the patients suf-
fered from side effects like polydipsia and polyuria.
 In an open study conducted by Micev and Lynch  [54] , 
these positive results could be confirmed. Six out of 8 pa-
tients experienced complete remission of self-harming 
behavior.
 An equal reduction in aggression and self-injurious 
behavior was shown in a retrospective study by Luchins 
and Dojka  [55] who assessed the effect of lithium and 
propanolol in subjects with mental retardation.
 In 1989, Glenn et al.  [56] published case reports of 10 
brain-injured patients with severe aggressive behavior. 
Five of these patients showed a dramatic response after 
onset of lithium treatment.
 A decrease in the frequency of aggressive outbursts 
was also demonstrated by Bellus et al.  [57] in patients fol-
lowing brain injury. The authors concluded that the use 
of lithium may yield positive effects in the control of ag-
gressive behavior, even in the long term.
 Adult Psychiatric Population 
 One of the first studies in this field was conducted by 
van Putten and Sanders  [58] . They treated 35 patients 
with chronic and incapacitating mental illness and re-
ported a favorable change in aggressive behavior during 
lithium medication. None of their patients was suffering 
from manic-depressive illness.
 Likewise remarkable results were found by Rifkin et 
al.  [59] . This research group in 1972 conducted a 6-week 
double-blind crossover trial with random allocation 
comparing lithium to placebo in patients with emotion-
ally unstable character disorder. In the view of Rifkin et 
al.  [59] , the persuasive improvement during the lithium 
treatment had to be explained either by hidden manic-
depressive illness or by a closely related condition.
 In 2001, Prado-Lima et al.  [60] examined 8 mothers 
with child abuse. Lithium significantly reduced their 
abusive behavior towards their children at day 30 and day 
60 of treatment compared with baseline. Especially the 
score for physical aggression towards other people showed 
a statistically significant reduction.
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 Adult patients with an attention-deficit/hyperactivity 
disorder were treated in a randomized double-blind 
crossover design by Dorrego et al.  [61] with lithium or 
methylphenidate. They received 8 weeks of methylpheni-
date hydrochloride treatment and 8 weeks of lithium 
treatment by random assignment. Aggression was mea-
sured with the Overt Aggression Scale. The authors con-
cluded that lithium might be beneficial in the treatment 
of adult attention-deficit/hyperactivity disorder and that 
lithium significantly alleviated a couple of behavioral 
problems including aggressive outbursts.
 Persons with Uncontrolled Rage Outbursts 
 One interesting approach towards the effectiveness of 
lithium in the treatment of aggression is to study indi-
viduals with uncontrolled rage outbursts such as inmates 
of prisons or correctional institutions. In the 1970s, a 
number of ‘prisoner studies’ were conducted to investi-
gate the effect of lithium on aggression.
 Twelve inmates with personality disorders (aggressive, 
sociopathic and schizoid) from a maximum security 
prison in Connecticut were investigated by Sheard  [62] 
who was the first to present study results comparing lith-
ium with placebo. Lithium reduced self-rated aggressive 
affect while also being associated with a lower incidence 
of disciplinary sanctions.
 Tupin et al.  [63] treated 27 inmates of the California 
Medical Facility selected because of serious repeated vio-
lent behavior with lithium for 10 months. The anti-ag-
gressive effect of lithium could be replicated. Participants 
of this study described an increased capacity to reflect on 
the consequences of actions and to control angry feelings 
while taking lithium.
 The only clinical trial on lithium and aggression in-
volving outpatients with uncontrolled fits of rage was 
conducted by Sheard  [64] . Twelve inmates with aggres-
sive behavior were treated with lithium for 4 months and 
after their release the patients were followed as outpa-
tients during 1–2 months of lithium treatment. A de-
creased number of serious aggressive episodes could be 
shown.
 The same authors conducted a 3-month, double-blind, 
placebo-controlled trial with 66 inmates from a medium-
security prison  [65] . Significantly fewer major infractions 
occurred in the lithium as compared to the placebo group. 
These results strengthen the evidence that lithium can 
have an inhibitory effect on impulsive aggressive behav-
ior.
 Potential Mechanism: The Role of Serotonin 
 The potential mechanisms of the anti-aggressive ef-
fects of lithium are unclear. Some authors  [66] pointed to 
the frequently combined occurrence of impulse control 
disorder and bipolar disorder and suggested a relation-
ship between both disorders. They discussed an underly-
ing common pathophysiological pathway. Animal and 
clinical studies have suggested a critical role for central 
serotonin function in this context. Lithium exerts sero-
tonin-enhancing effects  [67] and this might provide an 
explanation for a possible working mechanism in the re-
duction of aggressive behavior.
 Coccaro and colleagues  [68–70] could show an inverse 
covariation between peripheral markers of central 5-HT 
functions and impulsive aggressive behavior such as a re-
duced number of 5-HT transporters on platelets corre-
lated with aggressive behavior. However, the validity of 
studies allegedly corroborating these rather populist con-
cepts has been questioned  [71] .
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